NK-104. Hypolipidemic, HMG-CoA reductase inhibitor

Drugs of the Future

Volumn 23, Issue 8, 1998, Pages 847-859

  Sorbera, L A ^a   Leeson, P A ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG ACTIVITY; DRUG INDICATION; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HYPERLIPIDEMIA; NONHUMAN; REVIEW;

EID: 0031764986     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1998.023.08.468504     Document Type: Review

References (42)

1. Hiyama, T., Minami, T., Hanamoto, T., Reddy, G.B. (Sagami Chem. Res. Center). Optically active esters of 7-substd. 3,5-difunctionalized 6-heptenoic acids. EP 475627.
2. Kaiyama, T., Minami, T., Guntor, B., Sakota, R., Arai, K., Kobara, Y., Suzuki, M. (Sagami Chem. Res. Center). Optically active β,δ-diketo acid esters and their reduced forms. JP 94025092.
3. Takahashi, K., Minami, T., Ohara, Y., Hiyama, T. A new synthesis of HMG-CoA reductase inhibitor NK-104 through hydrosilylation-cross coupling reaction. Tetrahedron Lett 1993, 34: 8263-6.
4. Takahashi, K., Minami, T., Ohara, Y., Hiyama, T. Synthesis of an artificial HMG-CoA reductase inhibitor NK-104 via a hydrosilylation-cross-coupling reaction. Bull Chem Soc Jpn 1995, 68: 2649-56.
5. Miyachi, N., Yanagawa, Y., Iwasaki, H., Ohara, Y., Hiyama, T. A novel synthetic method of HMG-CoA reductase inhibitor NK-104 via a hydroboration-cross-coupling sequence. Tetrahedron Lett 1993, 34: 8267-70.
6. Takano, S., Kamikubo, T., Sugihara, T., Suzuki, M., Ogasawara, K. Enantioconvergent synthesis of a promising HMG-CoA reductase inhibitor NK-104 from both enantiomers of epichlorohydrin. Tetrahedron Asymmetry 1993, 4: 201-4.
7. Hiyama, T., Minami, T., Takahashi, K. Synthesis of artificial HMG-CoA reductase inhibitors based on the olefination strategy. Bull Chem Soc Jpn 1995, 68: 364-72.
8. Kaiyama, T., Minami, T., Yanagawa, E., Obara, Y. (Sagami Chem. Res. Center; Nissan Chem. Ind., Ltd.). Condensed pyridines mevalonolactone intermediates and their preparation method. JP 93310700.
9. Aoki, T., Nishimura, H., Nakagawa, S. et al. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Arzneim-Forsch-Drug Res 1997, 47: 904-9.
10. Suzuki, H., Yamazaki, H., Aoki, T., Tamaki, T., Sato, F., Kitahara, M., Saito, Y. Lipid-lowering and antiatherosclerotic effect of NK-104 (nisvastatin), a new synthetic HMG-CoA reductase inhibitor, in WHHL rabbits. 13th Int Symp Drugs Affect Lipid Metab (May 30-June 3, Florence) 1998, 53.
11. Suzuki, H., Tamaki, T., Aoki, T., Sato, F., Kitahara, M., Saito, Y. Inhibitory effect of NK-104 (nisvastatin), a new synthetic HMG-CoA reductase inhibitor, on VLDL secretion in guinea pigs. Liver perfusion studies after 2-week dosage. 13th Int Symp Drugs Affect Lipid Metab (May 30-June 3, Florence) 1998, 54.
12. Aoki, T., Nakagawa, S., Suzuki, H., Tamaki, T., Wada, Y., Yokoo, N., Kitahara, M., Saito, Y. Pharmacological studies on NK-104, a novel potent HMG-CoA reductase inhibitor (2). Plasma lipid-lowering effects in guinea pigs. Jpn J Pharmacol 1995, 67(Suppl. 1): Abst P1-54.
13. Aoki, T., Nakagawa, S., Suzuki, H., Tamaki, T., Sato, F., Kitahara, M., Saito, Y. LDL-receptor enhancing effect of NK-104 (nisvastatin) in HepG2 cells (in vitro) and in guinea pigs (in vivo). 13th Int Symp Drugs Affect Lipid Metab (May 30-June 3, Florence) 1998, 47.
14. Kitahara, M., Kanaki, T., Tamaki, T., Tanaka, S., Saito, Y. NK-104 (nisvastatin) suppresses foam cell formation induced by denatured low density lipoprotein in J774 macrophages. 13th Int Symp Drugs Affect Lipid Metab (May 30-June 3, Florence) 1998, 49.
15. Kitahara, M., Kanaki, T., Miyakoshi, C., Kamon, J., Tamaki, T., Tanaka, S., Saito, Y. NK-104 (nisvastatin) suppresses arterial neointimal thickening by endothelial injury in rabbits via inhibiting smooth muscle cell growth and fibronectin production. 13th Int Symp Drugs Affect Lipid Metab (May 30-June 3, Florence) 1998, 95.
16. Kitahara, M., Kanaki, T., Toyoda, K., Miyakoshi, C., Tanaka, S., Tamaki, T., Saito, Y. NK-104, a newly developed HMG-CoA reductase inhibitor, suppresses neointimal thickening by inhibiting smooth muscle cell growth and fibronectin production in balloon-injured rabbit carotid artery. Jpn J Pharmacol 1998, 77: 117-28.
17. Ooyen, C., Bersino, A.M., Catapano, A.L. NK-104, a potent HMG-CoA reductase inhibitor, increases intracellular degradation of apo B-100 and decreases its secretion in HepG2 cells. Atherosclerosis 1997, 134(1-2): Abst 2.P.71.
18. Yanagida, A., Hara, E., Yotsumoto, H., Yamamoto, M. Influence of NK-104, a novel HMG-CoA reductase inhibitor (HCRI), on inhibition of apoprotein B100-secretion and acceleration of apoprotein A-1-secretion from HepG2 cells. J Jpn Atheroscler Soc 1998, 25(Suppl.): Abst 80.
19. Umetani, M., Morikawa, S., Kodama, T., Saito, Y. NK-104 (nisvastatin): Comparative study on the time course of mRNA induction for LDL receptor and HMG-CoA reductase in HepG2 cells by HMG-CoA reductase inhibitors. 13th Int Symp Drugs Affect Lipid Metab (May 30-June 3, Florence) 1998, 128.
20. Kimata, H., Kojima, J., Fujino, H., Koide, T., Yamada, Y., Yoshimura, M., Nakabeppu, H., Nakaya, N., Saito, Y. Pharmacokinetics of NK-104 (nisvastatin) in animals and human. 13th Int Symp Drugs Affect Lipid Metab (May 30-June 3, Florence) 1998, 63.
21. Nakaya, N., Kojima, J., Kimata, H., Kuwahata, R., Narusima, H. NK-104: Efficacy and tolerance of a new synthetic HMG-CoA reductase inhibitor in hypercholesterolemic volunteers. 12th Int Symp Drugs Affect Lipid Metab (Nov 7-10, Houston) 1995, 137.
22. Yamada, N., Goto, Y., Saito, Y. Clinical effect of NK-104 (nisvastatin) on hyperlipidemia - Double-blind comparative dose-finding study in three parallel groups. 13th Int Symp Drugs Affect Lipid Metab (May 30-June 3, Florence) 1998, 129.
23. Kajinami, K., Koizumi, J., Miyamoto, S. et al. Efficacy of NK-104 (nisvastatin), a new totally synthetic HMG-CoA reductase inhibitor, in heterozygous familial hypercholesterolemia. 13th Int Symp Drugs Affect Lipid Metab (May 30-June 3, Florence) 1998, 63.
24. NK-104 development status. Kowa Co., Ltd. Company Communication 1998, July 7.
25. Sit, S.Y., Parker, R.A., Motoc, I., Han, W., Balasubramanian, N., Catt, J.D., Brown, P.J., Harte, W.E., Thompson, M.D., Wright, J.J. Synthesis, biological profile, and quantitative structure-activity relationship of a series of novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. J Med Chem 1990, 33: 2982-99.
26. Roth, B.D., Bocan, T.M.A., Blankley, C.J. et al. Relation between tissue selectivity and lipophilicity for inhibitors of HMG-CoA reductase. J Med Chem 1991, 34: 463-6.
27. Pietro, D.A., Mantell, G. Simvastatin: A new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 1990, 8: 220-8.
28. Roth, B.D., Blankley, C.J., Chucholowski, A.W. et al. Inhibitors of biosynthesis. 3. Tetrahydro-4-hydroxy-6-[2-(1H-pyrrol-1-yl)ethyl]-2H-pyran-2-one inhibitors of HMG-CoA reductase. 2. Effects of introducing substituents at positions three and four of the pyrrole nucleus. J Med Chem 1991, 34: 357-66.
29. Watanabe, M., Koike, H., Ishiba, T., Okada, T., Seo, S., Hirai, K. Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methylsulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptenoates, a novel series of HMG-CoA reductase inhibitors. Bioorg Med Chem 1997, 5: 437-44.
30. Connolly, P.J., Westin, C.D., Loughney, D.A., Minor, L.K. HMG-CoA reductase inhibitors: Design, synthesis, and biological activity of tetrahydroindazole-substituted 3,5-dihydroxy-6-heptenoic acid sodium salts. J Med Chem 1993, 36: 3674-85.
31. Began, J.R., Bruno, J.G., Gustafson, K., Amin, D., Neuenschwander, K., Perrone, M. Inhibitors of HMG-CoA reductase. Biological effects of a 6-[2-[2-(4-fluoro-3-methylphenyl)-4-substituted cyclohexe-1-en-1-yl]ethenyl]-4-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one. Eur J Med Chem 1992, 27: 735-42.
32. Karanewsky, D.S., Badia, M.C., Ciosek, C.P. Jr., Robl, J.A., Sofia, M.J., Simpkins, L.M., DeLange, B., Harrity, T.W., Biller, S.A., Gordon, E.M. Phosphorus-containing inhibitors of HMG-CoA reductase. 1. 4-[(2-Arylethyl)hydroxyphosphinyl]-3-hydroxybutanoic acids: A new class of cell-selective inhibitors of cholesterol biosynthesis. J Med Chem 1990, 33: 2952-6.
33. Bone, E.A., Davidson, A.H., Lewis, C.N., Todd, R.S. Synthesis and biological evaluation of dihydroeptastatin, a novel inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. J Med Chem 1992, 35: 3388-93.
34. Amin, D., Rutledge, R.Z., Needle, S.N. et al. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: Comparison with inhibitors of HMG-CoA reductase. J Pharmacol Exp Ther 1997, 281: 746-52.
35. Bischoff, H., Angerbauer, R., Bender, J., Bischoff, E., Faggiotto, A., Petzinna, D., Pfitzner, J., Porter, M.C., Schmidt, D., Thomas, G. Cerivastatin: Pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor. Atherosclerosis 1997, 135: 119-30.
36. Alberts, A.W., Chen, J., Kuron, G. et al. Mevinolin: A highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA 1980, 77: 3957-61.
37. Amin, D., Gustafson, S.K., Weinacht, J.M., Cornell, S.A., Neuenschwander, K., Kosmider, B., Scotese, A.C., Regan, J.R., Perrone, M.H. RG 12561 (dalvastatin): A novel synthetic inhibitor of HMG-CoA reductase and cholesterol-lowering agent. Pharmacology 1993, 46: 13-22.
38. Parker, R.A., Clark, R.W., Sit, S.-Y., Lanier, T.L., Grosso, R.A., Wright, J.J.K. Selective inhibition of cholesterol synthesis in liver versus extrahepatic tissues by HMG-CoA reductase inhibitors. J Lipid Res 1990, 31: 1271-82.
39. McTavish, D., Sorkin, E.M. Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs 1991, 42: 65-89.
40. Festal, D. Bervastatin. Drugs Fut 1995, 20: 1217-9.
41. Tsujita, Y., Kuroda, M., Shimada, Y. et al. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: Tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. Biochim Biophys Acta 1986, 877: 50-60.
42. Kramer, W., Wess, G., Enhsen, A. et al. Bile acid derived HMG-CoA reductase inhibitors. Biochim Biophys Acta 1994, 1227: 137-54.